Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:CHHNYSE:KSSNASDAQ:TGTXNASDAQ:UPST On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCHHChoice Hotels International$131.94+1.1%$126.94$116.13▼$157.86$6.13B0.96389,799 shs84,198 shsKSSKohl's$9.200.0%$8.00$6.04▼$23.09$1.03B1.668.99 million shs1.61 million shsTGTXTG Therapeutics$36.61+0.9%$36.92$16.65▼$46.48$5.81B1.912.90 million shs259,554 shsUPSTUpstart$73.68+0.4%$52.75$20.60▼$96.43$7.02B2.376.86 million shs1.88 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCHHChoice Hotels International+0.51%+4.03%+5.00%+1.79%+10.38%KSSKohl's+0.11%+13.30%+13.09%+38.45%-56.77%TGTXTG Therapeutics+2.51%-2.60%+1.51%-7.75%+98.20%UPSTUpstart+7.70%+17.54%+53.22%+89.69%+219.50%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCHHChoice Hotels International3.6054 of 5 stars2.00.01.71.61.94.21.9KSSKohl's3.6502 of 5 stars1.82.03.31.71.51.71.9TGTXTG Therapeutics3.7803 of 5 stars2.41.00.03.52.12.51.9UPSTUpstart3.3448 of 5 stars2.12.00.02.72.13.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCHHChoice Hotels International 1.92Reduce$131.31-0.48% DownsideKSSKohl's 1.53Reduce$9.756.01% UpsideTGTXTG Therapeutics 2.80Moderate Buy$40.8011.44% UpsideUPSTUpstart 2.29Hold$67.42-8.49% DownsideCurrent Analyst Ratings BreakdownLatest CHH, TGTX, KSS, and UPST Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2025UPSTUpstartPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeOverweight$75.006/23/2025CHHChoice Hotels InternationalJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageUnderweight$124.006/12/2025UPSTUpstartStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageEqual Weight$55.005/30/2025CHHChoice Hotels InternationalTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$144.00 ➝ $128.005/30/2025KSSKohl'sRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$8.00 ➝ $9.005/30/2025KSSKohl'sBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetUnderweight ➝ Underweight$4.00 ➝ $5.005/29/2025KSSKohl'sThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell ➝ Sell5/29/2025KSSKohl'sTelsey Advisory GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform ➝ Market Perform$9.005/22/2025KSSKohl'sTelsey Advisory GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform ➝ Market Perform$9.00 ➝ $9.005/19/2025CHHChoice Hotels InternationalRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$150.00 ➝ $145.005/19/2025KSSKohl'sJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetUnderweight ➝ Underweight$7.00 ➝ $8.00(Data available from 7/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCHHChoice Hotels International$1.58B3.86$9.34 per share14.13($0.97) per share-136.02KSSKohl's$16.22B0.06$8.21 per share1.12$33.73 per share0.27TGTXTG Therapeutics$329M17.67$0.12 per share295.09$1.43 per share25.60UPSTUpstart$636.53M11.01N/AN/A$6.94 per share10.62Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCHHChoice Hotels International$299.67M$6.5520.1517.812.2019.75%-377.51%13.07%8/6/2025 (Estimated)KSSKohl's$109M$1.098.457.54N/A0.75%4.71%1.27%8/27/2025 (Estimated)TGTXTG Therapeutics$23.38M$0.24152.5836.61N/A10.13%18.88%7.05%8/5/2025 (Estimated)UPSTUpstart-$128.58M-$0.75N/A79.22N/A-9.20%-15.27%-4.60%8/5/2025 (Estimated)Latest CHH, TGTX, KSS, and UPST EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/29/2025Q1 2026KSSKohl's-$0.22-$0.13+$0.09-$0.13$3.01 billion$3.05 billion5/8/2025Q1 2025CHHChoice Hotels International$1.38$1.34-$0.04$0.94$348.52 million$332.86 million5/7/2025Q1 2025TGTXTG Therapeutics$0.19$0.03-$0.16$0.03$117.07 million$120.86 million5/6/2025Q1 2025UPSTUpstart$0.19$0.30+$0.11-$0.03$201.08 million$213.37 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCHHChoice Hotels International$1.150.87%N/A17.56%N/AKSSKohl's$0.505.44%N/A45.87%N/ATGTXTG TherapeuticsN/AN/AN/AN/AN/AUPSTUpstartN/AN/AN/AN/AN/ALatest CHH, TGTX, KSS, and UPST DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/14/2025CHHChoice Hotels Internationalquarterly$0.28750.91%7/1/20257/1/20257/16/20255/14/2025KSSKohl'squarterly$0.12506.21%6/11/20256/11/20256/25/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCHHChoice Hotels InternationalN/A0.840.84KSSKohl's0.951.090.14TGTXTG Therapeutics1.034.023.04UPSTUpstartN/A0.560.56Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCHHChoice Hotels International65.57%KSSKohl's98.04%TGTXTG Therapeutics58.58%UPSTUpstart63.01%Insider OwnershipCompanyInsider OwnershipCHHChoice Hotels International23.78%KSSKohl's1.00%TGTXTG Therapeutics10.64%UPSTUpstart16.67%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCHHChoice Hotels International1,70046.40 million35.37 millionOptionableKSSKohl's87,000112.04 million110.92 millionOptionableTGTXTG Therapeutics290158.76 million141.86 millionOptionableUPSTUpstart1,19395.14 million79.28 millionOptionableCHH, TGTX, KSS, and UPST HeadlinesRecent News About These CompaniesThese Artificial Intelligence (AI) Stocks Are Quietly Outperforming the MarketJune 30 at 8:17 PM | fool.comIs Upstart Too Expensive Now? A Wait-and-See Approach May HelpJune 30 at 2:16 PM | zacks.com2 Artificial Intelligence (AI) Stocks (Besides Nvidia) to Buy Hand Over Fist for the Long TermJune 28, 2025 | fool.comUpstart Stock Appreciates 40% QTD: Should You Take the Bait?June 27, 2025 | zacks.comFintech Stock Breaking Above Key Resistance LevelsJune 27, 2025 | schaeffersresearch.comUpstart Holdings, Inc. (UPST) Exceeds Market Returns: Some Facts to ConsiderJune 26, 2025 | zacks.comUpstart Holdings, Inc. (UPST) Is a Trending Stock: Facts to Know Before Betting on ItJune 26, 2025 | zacks.comUpstart Holdings, Inc. (NASDAQ:UPST) Receives Consensus Rating of "Hold" from BrokeragesJune 24, 2025 | americanbankingnews.comHere's Why Upstart Holdings, Inc. (UPST) Fell More Than Broader MarketJune 20, 2025 | zacks.comThis Nuclear Upstart Is Crushing the Market. Should You Plug In?June 20, 2025 | fool.comBlock vs. Upstart: Which Fintech Stock Has More Upside in 2025?June 13, 2025 | zacks.comUpstart Holdings, Inc. (UPST) Stock Declines While Market Improves: Some Information for InvestorsJune 12, 2025 | zacks.comKBRA Assigns Preliminary Ratings to Upstart Securitization Trust 2025-2June 11, 2025 | businesswire.comInvestors Heavily Search Upstart Holdings, Inc. (UPST): Here is What You Need to KnowJune 11, 2025 | zacks.comUpstart Holdings, Inc. (UPST) Morgan Stanley US Financials, Payments & CRE Conference TranscriptJune 10, 2025 | seekingalpha.comTradr Launches First Ever Leveraged ETFs on Archer Aviation and Upstart HoldingsJune 10, 2025 | prnewswire.com2 AI Stocks Down 49% and 86% to Buy Before They Soar, According to Certain Wall Street AnalystsJune 9, 2025 | fool.com2 No-Brainer Artificial Intelligence (AI) Stocks to Buy on the DipJune 7, 2025 | fool.comSell Upstart Holdings: Hard To Deliver On Its PromisesJune 4, 2025 | seekingalpha.comUpstart Holdings, Inc. (UPST) Bank of America Global Technology Conference (Transcript)June 3, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense3 Growth Stocks Too Small for Institutions to BuyBy Gabriel Osorio-Mazilli | June 19, 2025View 3 Growth Stocks Too Small for Institutions to BuyUpstart Stock’s Bull Case Just Got a Lot StrongerBy Gabriel Osorio-Mazilli | June 13, 2025View Upstart Stock’s Bull Case Just Got a Lot StrongerCHH, TGTX, KSS, and UPST Company DescriptionsChoice Hotels International NYSE:CHH$131.94 +1.42 (+1.09%) As of 11:10 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Choice Hotels International, Inc., together with its subsidiaries, operates as a hotel franchisor in the United States and internationally. It operates through Hotel Franchising & Management and Corporate & Other segments. The company franchises lodging properties under the brand names of Comfort Inn, Comfort Suites, Quality, Clarion, Clarion Pointe, Sleep Inn, Ascend Hotel Collection, Econo Lodge, Rodeway Inn, MainStay Suites, Suburban Studios, WoodSpring Suites, Everhome Suites, Cambria Hotels, Radisson Blu, Radisson RED, Radisson, Park Plaza, Country Inn & Suites by Radisson, Radisson Inn & Suites, Park Inn by Radisson, Radisson Individuals, and Radisson Collection. Choice Hotels International, Inc. was founded in 1939 and is headquartered in North Bethesda, Maryland.Kohl's NYSE:KSS$9.20 0.00 (-0.03%) As of 11:10 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Kohl's Corporation operates as an omnichannel retailer in the United States. It offers branded apparel, footwear, accessories, beauty, and home products through its stores and website. The company provides its products primarily under the brand names of Croft & Barrow, Jumping Beans, SO, Sonoma Goods for Life, and Tek Gear, as well as Food Network, LC Lauren Conrad, Nine West, and Simply Vera Vera Wang. Kohl's Corporation was founded in 1988 and is headquartered in Menomonee Falls, Wisconsin.TG Therapeutics NASDAQ:TGTX$36.61 +0.32 (+0.89%) As of 11:10 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.Upstart NASDAQ:UPST$73.68 +0.29 (+0.39%) As of 11:10 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Upstart Holdings, Inc., together with its subsidiaries, operates a cloud-based artificial intelligence (AI) lending platform in the United States. Its platform includes personal loans, automotive retail and refinance loans, home equity lines of credit, and small dollar loans that connects consumer demand for loans to its to bank and credit unions. Upstart Holdings, Inc. was founded in 2012 and is headquartered in San Mateo, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Nike's Stock Just Got an Upgrade: Is a Real Comeback Brewing? Why Hims & Hers Is a Buy Below $35 After Its 16% Pullback Jefferies Raises Broadcom Price Target to $315: 19% Upside Ahead Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
